JenaValve

Hendrik Treede; Ardawan Rastan; Markus Ferrari; Stephan Ensminger; Hans Reiner Figulla; Friedrich Wilhelm Mohr

doi:10.4244/EIJV8SQA16

JenaValve

Hendrik Treede^*, Ardawan Rastan, Markus Ferrari, Stephan Ensminger, Hans Reiner Figulla, Friedrich Wilhelm Mohr

^*Corresponding author for this work

Clinic of Cardiac and Thoracic Vascular Surgery

30 Citations (Scopus)

Abstract

The JenaValve™ is a next-generation TAVI device which consists of a well-proven porcine root valve mounted on a low-profile nitinol stent. Feeler guided positioning and clip fixation on the diseased leaflets allow for anatomically correct implantation of the device without rapid pacing. Safety and efficacy of transapical aortic valve implantation using the JenaValveo were evaluated in a multicentre prospective study that showed good short and midterm results. The valve was CE-mark released in Europe in September 2011. A post-market registry ensures on-going and prospective data collection in "real-world" patients. The transfemoral JenaValveo delivery system will be evaluated in a first-in-man study in the near future.

Original language	English
Journal	EuroIntervention
Volume	8
Pages (from-to)	Q88-Q93
ISSN	1774-024X
DOIs	https://doi.org/10.4244/EIJV8SQA16
Publication status	Published - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.4244/EIJV8SQA16

Cite this

@article{b8ba1aa379b049599bf4daa39a78967e,

title = "JenaValve",

abstract = "The JenaValve{\texttrademark} is a next-generation TAVI device which consists of a well-proven porcine root valve mounted on a low-profile nitinol stent. Feeler guided positioning and clip fixation on the diseased leaflets allow for anatomically correct implantation of the device without rapid pacing. Safety and efficacy of transapical aortic valve implantation using the JenaValveo were evaluated in a multicentre prospective study that showed good short and midterm results. The valve was CE-mark released in Europe in September 2011. A post-market registry ensures on-going and prospective data collection in {"}real-world{"} patients. The transfemoral JenaValveo delivery system will be evaluated in a first-in-man study in the near future.",

author = "Hendrik Treede and Ardawan Rastan and Markus Ferrari and Stephan Ensminger and Figulla, {Hans Reiner} and Mohr, {Friedrich Wilhelm}",

year = "2012",

doi = "10.4244/EIJV8SQA16",

language = "English",

volume = "8",

pages = "Q88--Q93",

journal = "EuroIntervention",

issn = "1774-024X",

publisher = "Europa Digital & Publishing",

}

TY - JOUR

T1 - JenaValve

AU - Treede, Hendrik

AU - Rastan, Ardawan

AU - Ferrari, Markus

AU - Ensminger, Stephan

AU - Figulla, Hans Reiner

AU - Mohr, Friedrich Wilhelm

PY - 2012

Y1 - 2012

N2 - The JenaValve™ is a next-generation TAVI device which consists of a well-proven porcine root valve mounted on a low-profile nitinol stent. Feeler guided positioning and clip fixation on the diseased leaflets allow for anatomically correct implantation of the device without rapid pacing. Safety and efficacy of transapical aortic valve implantation using the JenaValveo were evaluated in a multicentre prospective study that showed good short and midterm results. The valve was CE-mark released in Europe in September 2011. A post-market registry ensures on-going and prospective data collection in "real-world" patients. The transfemoral JenaValveo delivery system will be evaluated in a first-in-man study in the near future.

AB - The JenaValve™ is a next-generation TAVI device which consists of a well-proven porcine root valve mounted on a low-profile nitinol stent. Feeler guided positioning and clip fixation on the diseased leaflets allow for anatomically correct implantation of the device without rapid pacing. Safety and efficacy of transapical aortic valve implantation using the JenaValveo were evaluated in a multicentre prospective study that showed good short and midterm results. The valve was CE-mark released in Europe in September 2011. A post-market registry ensures on-going and prospective data collection in "real-world" patients. The transfemoral JenaValveo delivery system will be evaluated in a first-in-man study in the near future.

UR - http://www.scopus.com/inward/record.url?scp=84885421871&partnerID=8YFLogxK

U2 - 10.4244/EIJV8SQA16

DO - 10.4244/EIJV8SQA16

M3 - Journal articles

C2 - 22995119

AN - SCOPUS:84885421871

SN - 1774-024X

VL - 8

SP - Q88-Q93

JO - EuroIntervention

JF - EuroIntervention

ER -

JenaValve

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this